Log In
Print
BCIQ
Print
Print this Print this
 

Xenopax

  Manage Alerts
Collapse Summary General Information
Company Shanghai CP Guojian Pharmaceutical Co. Ltd.
DescriptionHumanized mAb against interleukin-2 (IL-2) receptor alpha chain (CD25)
Molecular Target Interleukin-2 (IL-2) receptor alpha chain (CD25)
Mechanism of ActionBiosimilar
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentMarketed
Standard IndicationRenal transplant
Indication DetailsPrevent renal transplant rejection
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today